EP1 - 生醫界的「頭彩理論」：為何腫瘤免疫新藥值得長線佈局？The Game in IO

【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作 生技投資常被視為高風險的博弈，但在資深投資者眼中，這是一場關於「勝率」與「倍數」的賽局 。本集邀請漢康生技創辦人劉世高博士，以他帶領團隊研發出台灣首個獲歐盟批准創新藥的實戰經驗，剖析為何他選擇投入僅有 1.6% 企業敢挑戰的「多功能融合蛋白」賽道。 劉博士將分享生醫界獨特的「頭彩理論」：當一個標靶能同時啟動多種免疫機制，它的商業回報將不再是單一產品，而是具備全球競爭力的戰略資產。讓我們與漢康一起，看見數據背後的商業邏輯，讀懂這場正在發生的抗癌革命 。 While biotech investing is often viewed as a high-stakes gamble, seasoned investors see it as a calculated game of odds and multiples. In this episode, we are joined by Dr. Scott Liu, founder of HanchorBio. Drawing on his battle-tested experience leading the team behind Taiwan’s first innovative drug to receive EU approval, he dissects his decision to enter the "multifunctional fusion protein" arena—a path fewer than 1.6% of companies dare to tread. Dr. Liu unveils the biomedical sector’s unique "Jackpot Theory": when a single target can simultaneously trigger multiple immune mechanisms, the payoff transcends a mere product—it becomes a strategic asset with global competitiveness. Join us to uncover the business logic behind the data and decipher the anti-cancer revolution unfolding before our eyes. 漢康生技官網：https://www.hanchorbio.com/ 漢康生技LinkedIn：https://reurl.cc/7b19y9 本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。